Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage-Reference-Cited by-同舟云学术

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage

Published:2018-02-08 Issue:6 Volume:131 Page:649-661
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Li Juan¹²,Prins Daniel¹²,Park Hyun Jung¹²,Grinfeld Jacob¹²³,Gonzalez-Arias Carlos¹²³,Loughran Stephen¹²,Dovey Oliver M.⁴,Klampfl Thorsten¹²,Bennett Cavan²⁵,Hamilton Tina L.¹²,Pask Dean C.¹²,Sneade Rachel¹²,Williams Matthew¹²,Aungier Juliet¹²,Ghevaert Cedric²⁵,Vassiliou George S.³⁴,Kent David G.¹²,Green Anthony R.¹²³

Affiliation:

1. Cambridge Institute for Medical Research and Wellcome Trust/Medical Research Council Stem Cell Institute and

2. Department of Haematology, University of Cambridge, Cambridge, United Kingdom;

3. Department of Haematology, Addenbrooke’s Hospital, Cambridge, United Kingdom;

4. Wellcome Trust Sanger Institute, Cambridge, United Kingdom; and

5. National Health Service Blood and Transplant, Cambridge, United Kingdom

Abstract

Key Points Mutant CALR drives ET and MF in knockin mice. Mutant CALR expression results in expansion of phenotypic HSCs without a self-renewal advantage.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/6/649/1466743/blood806356.pdf

Reference53 articles.

1. Myeloproliferative neoplasm stem cells;Mead;Blood,2017

2. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms;Vainchenker;Blood,2017

3. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms;Grinfeld;Haematologica,2017

4. The myeloproliferative disorders;Campbell;N Engl J Med,2006

5. How I treat essential thrombocythemia;Beer;Blood,2011

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements;Cancers;2024-01-25

2. Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes;Cell Genomics;2023-12

3. Circulating Platelets Modulate Oligodendrocyte Progenitor Cell Differentiation During Remyelination;2023-09-22

4. Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling;Cancers;2023-09-21

5. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms;Nature Cancer;2023-08-07